Event Schedule

Have a look at Schedule

08:00 - 08:50

Registration & Itinerary Collection

08:50 - 09:00

Chairperson Welcome Address

Leo Kirkovsky

Sr. Director

exelixis
09:00

Keynote Presentation 1: The World Is Changing, We Must Adapt

Hong Cheng

VP, Head of Research Strategy

Sanofi

Emerging Trends in Oncology

9:25

Presentation 2: Botanical drugs for cancer therapeutics

Igor Nasonkin

Founder, CEO & Chief Scientific Officer

Phythera Therapeutics, Inc
9:50

Presentation 3: Next Generation RNA-Based Therapeutics in Oncology: Current Progress & Future Prospects

Dinesh Chandra

Independent Biotech Consultant

Johnson & Johnson (Former)
10:15

Coffee Break & Networking Session

Fragment Based Drug Discovery

11:05

Presentation 4: Recent results from massively multitask Profile-QSAR models as accurate as 4-point IC50s for 9000 assays

Eric Martin

Director of Computational Chemistry

Novartis
11:30

Presentation 5: MolecuLernTM Driven Deep Learning Empirical Models In Fragment-Based Design and Development of Small Molecules and Degraders Targeting (un)Druggable Protein Targets

Hariprasad Vankayalapati, M. Pharm., PhD

Chief Scientific Officer

Biolexis Therapeutics, Inc.
11:55

Data Driven Presentation: Applying gut-derived organoids to drug discovery

Linda A. Lieberman

Head of Mucosal Biology Research, Discovery Immunology

Merck Research Laboratories
12:20

Networking Lunch

Drug Development Innovations

13:20

Case Study Presentation: In vitro/vivo Evaluation of an Ultra-potent Rifampicin Based Antibiotic

Dr. Thomas Nittoli

Senior Director, R&D Chemistry

Regeneron Pharmaceuticals, Inc
13:45

Presentation 6: Engineering Proteolysis-Targeting Antibodies (PROTABs) for degradation of cell surface receptors

Yee Seir (Sheil) Kee

Scientist III

Genentech
14:10

Case Study Presentation: Designing Therapies with Nature's Codebook: Human Genetics

Karol Estrada

VP Translational Genomics

Maze Therapeutics
14:35

Deep Dive Presentation: Collaborative Approaches in Drug Development:

  • Showcasing successful collaborations between industry and academia. Discussing the role of partnerships in driving innovation in drug discovery

Ekundayo Osimboni, MBA, PMP

Sr. Director, Strategic Alliance & Partnership Management

Foghorn Therapeutics Inc
15:00

Keynote Presentation: Optimizing Drug Development Strategies Across Therapeutic Areas: Insights from Clinical Pharmacology and Translational Research

Alan Xiao

CSO, Sr Consultant

StarDecisis
15:25

Collaborative Conversation: Case Studies and Success Stories:

  • Real-world examples of successful drug discoveries.
  • Lessons learned and best practices.

Moderator:-

Dr. Thomas Nittoli

Senior Director, R&D Chemistry

Regeneron Pharmaceuticals, Inc

Panelists:-

Hariprasad Vankayalapati, M. Pharm., PhD

Chief Scientific Officer

Biolexis Therapeutics, Inc.

Dinesh Chandra

Independent Biotech Consultant

Johnson & Johnson (Former)
16:00

Chair Closing Remarks

Leo Kirkovsky

Sr. Director

exelixis
16:05

Happy Hours Networking

08:00 - 08:50

Registration & Itinerary Collection

08:50 - 09:00

Chair Welcome Address

Leo Kirkovsky

Sr. Director

exelixis

Development of Next Gen Therapeutics

9:00

Presentation 7: Unlocking polypharmacological profiles of drugs to innovate for new drug design

Julie Owen

Director of Chemistry

Recursion
9:25

Presentation 8: From Genes to Therapies: Multi-omic approaches in Oncology extra cellular target discovery

Satyajit Rajapurkar

Investigator

GSK
9:50

Data Driven Presentation: Development of Exercise Mimetics for Treatment of Obesity

Thomas Burris

Director of University of Florida Genetics Institute and Dean's Professor || Scientific Co-Founder

Pelagos Therapeutics
10:15

Coffee Break & Networking Session

AI & ML

11:05

Presentation 9: Artificial Intelligence-driven Target and Antibody Therapeutics Discovery from Human Sequencing Data

Xingfeng Bao

VP, Head of Biology

GV20 Therapeutics
11:30

Case Study Presentation: Combining DNA Encoded library screening and machine learning to accelerate molecule drug discovery

G. Joseph Franklin

Senior Vice President and Head of Early Discovery

Anagenex
11:55

Presentation 10: Streamlining Drug Development with Integrated Labs, Automation, and Machine Learning

Ilja Kuesters

Associate Director

Generate: Biomedicines
12:20

Case Study Presentation: Accelerating Oncology Drug Discovery with AI/ML: Predicting Protein-Ligand Binding Using Generative Models

Sai Krishna Sirumalla

Research Scientist, Machine Learning

Iambic
12:45

Lunch Break

13:45

Deep Dive Presentation: ML-based approaches for multi-parameter optimization of protein therapeutics

Tate Tabtieng

Senior Scientist

Generate Biomedicines

Synergies in Drug Innovation:

14:10

Presentation 11: Reprogramming Protein Targets for Therapeutic Benefit

Alexandra Joseph

Executive Vice President Biology

Exo Therapeutics
14:35

Presentation 12: The Naturopathic Treatment of Cancer and Chronic Diseases with immunotherapy via Immunomodulation

Eric Scheinbart M.D.

MD

Intlmed
15:00

Interactive Panel: Harnessing Artificial Intelligence in Drug Discovery: Strategies, Challenges, and Future Directions

Moderator:-

Istvan Enyedy

Senior Principal Scientist

UCB

Panelists:-

Ilja Kuesters

Associate Director

Generate: Biomedicines

Xingfeng Bao

VP, Head of Biology

GV20 Therapeutics

Alexandra Joseph

Executive Vice President Biology

Exo Therapeutics

G. Joseph Franklin

Senior Vice President and Head of Early Discovery

Anagenex
15:45

Chair Closing Remarks

Leo Kirkovsky

Sr. Director

exelixis
15:50

End of Day 2

020 3004 8847

info@worldbigroup.com

WorldBI, Office 7, 35-37 Ludgate Hill, London. EC4M 7JN

Canada Office: 55 Village Centre Place, Suite 200, Mississauga, ON, L4Z 1VP

Quick Links

Home

Contact Us

About Us

Our Conferences

Faq

About World BI

World BI is a leading designer, developer and deliverer of strategic conferences, professional training, business-to-business meetings and online information. We maintain the highest standards of quality and services in market research, technology, business as well as product development.